Top Industry Leaders in the Dural Arteriovenous Fistulas Treatment Market
Latest Dural Arteriovenous Fistulas Treatment Companies Updates:
Cedars-Sinai Medical Center initiates a clinical trial This study investigates the safety and efficacy of a novel embolic device for treating DAVFs. The device aims to offer a minimally invasive option with potentially shorter recovery times compared to traditional surgery.
Mayo Clinic publishes research on flow diverter stents This study demonstrates the effectiveness of flow diverter stents in closing DAVFs, potentially providing an alternative to surgery for high-risk patients.
Acteon acquires FlowCardia This December 2023 deal strengthens Acteon's position in the neurovascular market by adding FlowCardia's expertise in DAVF treatment devices.MicroVention partners with University of California, San Francisco: This collaboration aims to develop and commercialize next-generation embolic materials for DAVF treatment, focusing on improved targeting and efficacy.
List of Dural Arteriovenous Fistulas Treatment Key companies in the market:
- BD (U.S.)
- Medtronic (U.S.)
- B. Braun Melsungen AG (Germany)
- Cook (U.S.)
- Teleflex Incorporated (U.S.)
- Fresenius Medical Care AG & Co. KGaA (Germany)
- NxStage Medical, Inc.(U.S.)
- Poly Medicure Limited